ACell Announces CE Mark Approval
Milestone Paves the Way for MicroMatrix and Cytal Wound Management Devices in European Union
News provided by
Share this article
Share this article
COLUMBIA, Md., Dec. 22, 2020 /PRNewswire/ ACell, Inc., a leading regenerative medicine company, announced today that it has received CE mark approval for its MicroMatrix®, Cytal® Wound Matrix, and Cytal® Burn Matrix devices. This regulatory approval allows ACell to distribute these products throughout the 27 countries of the European Union.
President and CEO Patrick McBrayer said, The CE Mark approval is a significant accomplishment for ACell, which required rigorous regulatory review against stringent safety and clinical standards. We are proud to be one step further to offering our wound management products to patients and their health care providers throughout Europe.